rituximab

Response to: ‘Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’’ by Westhoff et al
Michael Bonelli, Daniel Aletaha

Annals of the Rheumatic Diseases Oct 2021, 80 (10) e163; DOI: 10.1136/annrheumdis-2021-220764
Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et al
Caoilfhionn Marie Connolly, Darya Koenig, Srekar N Ravi, Antoine Azar, Sam Kant, Monika Dalal, Jessica Duchen, Philip Seo, Brendan Antiochos, Julie J Paik, Duvuru Geetha

Annals of the Rheumatic Diseases Oct 2021, 80 (10) e164; DOI: 10.1136/annrheumdis-2021-220972
Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et al
Sarah H Chung, Mark Wener, Alison M Bays, Habib Rahbar, Chihiro Morishima, Andrew B Bryan, Susan L Fink, Seth Cohen, Nandita S Mani, Anu Chaudhary, Gregory C Gardner

Annals of the Rheumatic Diseases Oct 2021, 80 (10) e165; DOI: 10.1136/annrheumdis-2021-220957
Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response”by Bonelli et al
Maurizio Benucci, Arianna Damiani, Maria Infantino, Mariangela Manfredi, Valentina Grossi, Barbara Lari, Francesca Li Gobbi, Piercarlo Sarzi Puttini

Annals of the Rheumatic Diseases Oct 2021, 80 (10) e166; DOI: 10.1136/annrheumdis-2021-220829
Response to: Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et al
Michael Bonelli, Daniel Aletaha

Annals of the Rheumatic Diseases Oct 2021, 80 (10) e167; DOI: 10.1136/annrheumdis-2021-220997
Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
O Flossmann, R B Jones, D R W Jayne, R A Luqmani

Annals of the Rheumatic Diseases Jul 2006, 65 (7) 841-844; DOI: 10.1136/ard.2005.048900
Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations
P M Aries, B Hellmich, J Voswinkel, M Both, B Nölle, K Holl-Ulrich, P Lamprecht, W L Gross

Annals of the Rheumatic Diseases Jul 2006, 65 (7) 853-858; DOI: 10.1136/ard.2005.044420
Repeated B cell depletion in treatment of refractory systemic lupus erythematosus
K P Ng, M J Leandro, J C Edwards, M R Ehrenstein, G Cambridge, D A Isenberg

Annals of the Rheumatic Diseases Jul 2006, 65 (7) 942-945; DOI: 10.1136/ard.2005.044487
Rituximab in the treatment of antisynthetase syndrome
L Brulhart, J-M Waldburger, C Gabay

Annals of the Rheumatic Diseases Jul 2006, 65 (7) 974-975; DOI: 10.1136/ard.2005.045898
Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia
Philippe Guilpain, Clément Le Bihan, Vincent Foulongne, Patrice Taourel, Nathalie Pansu, Alexandre Thibault Jacques MARIA, Boris Jung, Romaric Larcher, Kada Klouche, Vincent Le Moing

Annals of the Rheumatic Diseases Jan 2021, 80 (1) e10; DOI: 10.1136/annrheumdis-2020-217549

Main menu

rituximab

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

rituximab

Pages